市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Climb Bio, Inc. | 混合的 | - |
AIStockmoo 评分
0.8
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -1.5 |
| 平均 | 0.75 |
|
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 8.07% |
| 机构持股比例 | 85.01% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 9.00 (Baird, 662.71%) | 购买 |
| 9.00 (HC Wainwright & Co., 662.71%) | 购买 | |
| 中 | 9.00 (662.71%) | |
| 低 | 8.00 (BTIG, 577.97%) | 购买 |
| 平均值 | 8.67 (634.75%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 1.95 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 16 Oct 2025 | 8.00 (577.97%) | 购买 | 1.95 |
| 30 Sep 2025 | 8.00 (577.97%) | 购买 | 2.01 | |
| HC Wainwright & Co. | 13 Oct 2025 | 9.00 (662.71%) | 购买 | 2.00 |
| Baird | 15 Aug 2025 | 9.00 (662.71%) | 购买 | 1.90 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合